Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons

Transplant Infectious Disease

Volumn 19, Issue 2, 2017, Pages

  Falsey, Ann R ^a   Koval, Christine ^b   DeVincenzo, John P ^c   Walsh, Edward E ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c LE BONHEUR CHILDREN'S MEDICAL CENTER   (United States)

Author keywords

immunoglobulin; pneumonia; respiratory syncytial virus; RI 001; transplant

Indexed keywords

ANTIVIRUS AGENT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RI 001; RIBAVIRIN; UNCLASSIFIED DRUG; NEUTRALIZING ANTIBODY; NEW DRUG; VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL OUTCOME; COMPASSIONATE USE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; ENGRAFTMENT; FEMALE; HEMATOLOGIC MALIGNANCY; HEP-2 CELL LINE; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOCOMPROMISED PATIENT; INFANT; INFECTION RISK; LIVER GRAFT; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEVERE COMBINED IMMUNODEFICIENCY; CLINICAL TRIAL; DRUG APPROVAL; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PRESCHOOL CHILD; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COMPASSIONATE USE TRIALS; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; INFUSIONS, INTRAVENOUS; INVESTIGATIONAL NEW DRUG APPLICATION; MALE; MIDDLE AGED; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85014424064     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12657     Document Type: Article

References (29)

1. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis. 2001;183:16–22.
2. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352:1749–1759.
3. Englund JA, Sullivan CJ, Jordan MC, Dehner LP, Vercellotti GM, Balfour HH. Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med. 1988;109:203–208.
4. Schiffer JT, Kirby K, Sandmaier B, Storb R, Corey L, Boeckh M. Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica. 2009;94:1101–1108.
5. Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996;22:778–782.
6. Kim YJ, Guthrie KA, Waghmare A, et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: Factors determining progression to lower respiratory tract disease. J Infect Dis. 2014;209:1195–1204.
7. Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: Combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant. 2000;25:751–755.
8. Chemaly RF, Shah DP, Boeckh MJ. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;59(Suppl 5):S344–S351.
9. Shah DP, Ghantoji SS, Shah JN, et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother. 2013;68:1872–1880.
10. Chemaly RF, Torres HA, Munsell MF, et al. An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis. 2012;206:1367–1371.
11. Waghmare A, Englund JA, Boeckh M. How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation. Blood. 2016;127:2682–2692.
12. DeVincenzo JP, Hirsch RL, Fuentes RJ, Top FH Jr. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation – A compassionate use experience. Bone Marrow Transplant. 2000;25:161–265.
13. Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis. 2001;184:350–354.
14. Beaird OE, Freifeld A, Ison MG, et al. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: A survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis. 2016;18:210–215.
15. Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis. 2004;190:373–378.
16. Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: Single-center study and review of the literature. Clin Infect Dis. 2008;46:402–412.
17. DeVincenzo JP, McClure MW, Symons JA, et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med. 2015;373:2048–2058.
18. DeVincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med. 2014;371:711–722.
19. Luchsinger V, Piedra PA, Ruiz M, et al. Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus. Clin Infect Dis. 2012;54:905–912.
20. Ramilo O, Lagos R, Saez-Llorens X, et al. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J. 2014;33:703–709.
21. Boukhvalova M, Blanco JC, Falsey AR, Mond J. Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus. Bone Marrow Transplant. 2016;51:119–126.
22. Aschermann S, Lux A, Baerenwaldt A, Biburger M, Nimmerjahn F. The other side of immunoglobulin G: Suppressor of inflammation. Clin Exp Immunol. 2010;160:161–167.
23. Lehners N, Schnitzler P, Geis S, et al. Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit. Bone Marrow Transplant. 2013;48:1548–1553.
24. Orange JS, Du W, Falsey AR. Therapeutic immunoglobulin selected for high antibody titer to RSV also contains high antibody titers to other respiratory viruses. Front Immunol. 2015;28:431.
25. Zhao X, Sullender WM. In vivo selection of respiratory syncytial viruses resistant to palivizumab. J Virol. 2005;797:3962–3968.
26. Zhu Q, McAuliffe JM, Patel NK, et al. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J Infect Dis. 2011;203:674–682.
27. Wasserman RL, Lumry W, Harris J 3rd, et al. Efficacy, safety and pharmacokietics of a new 10% liquid intravenous immunoglobulin containing high titer neutralizing antibody to rsv and other respiratory pathogens in subjects with primary immunodeficiency disease. J Clin Immunol. 2016;36:590–599.
28. Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis. 2013;56:258–266.
29. Dignan FL, Clark A, Aitken C, et al. BCSH/BSBMT/UK clinical virology network guideline: Diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation. Br J Haematol. 2016;173:380–393.